News Novo Nordisk fight with KBP Bio will go to arbitration Singapore court keeps an asset freeze on KBP Bio, saying the merits of its dispute with Novo Nordisk over a licensing deal must go to arbitration.
News Novo, Lilly trade oral GLP-1 data readouts at ECO Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.
News Novo says high-dose Wegovy can cause 28% weight loss Novo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.
News Cellular Intelligence scoops up Novo's Parkinson's therapy Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence.
News Novo Nordisk microRNA drug fluffs its lines in heart failure A microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure.
News Novo Nordisk buoyed by outperforming oral Wegovy in Q1 Shares in Novo Nordisk rose this morning after its highly anticipated first-quarter results revealed better-than-expected uptake of oral Wegovy.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.